Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?
Zoe N. Memel, Jeffrey Wang, Kathleen E. Corey – 2 February 2022
p21‐activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2‐related factor 2 phosphorylation
Yuancheng Mao, Chang Yeob Han, Lihua Hao, Younho Lee, Jung Beom Son, Hwangeun Choi, Mi Rin Lee, Jae Do Yang, Suk Kyun Hong, Kyung‐Suk Suh, Hee Chul Yu, Nam Doo Kim, Eun Ju Bae, Byung‐Hyun Park – 1 February 2022
Letter to the editor: Is transjugular intrahepatic portosystemic shunt the best treatment for adults without cirrhosis with extrahepatic portal vein obstruction and portal hypertension?
Caroline P. Lemoine, Riccardo Superina – 1 February 2022
KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration
Haihong Wang, Biying Zhang, Ruiqi Li, Jiayuan Chen, Guojie Xu, Ying Zhu, Jiao Li, Qing Liang, Qingling Hua, Lanqing Wang, Lu Wen, Min Jin, Jun Fan, Dejun Zhang, Lei Zhao, Dandan Yu, Zhenyu Lin, Jinghua Ren, Tao Zhang – 1 February 2022
When the Sun Sets, Who Doth Not Look for Night?
Randi J. Ryan, Timucin Taner, Julie K. Heimbach – 1 February 2022
Viral integrations in chronic hepatitis B infection: Purposeless passenger or problematic promoter of persistence?
Thomas Tu, Henrik Zhang – 1 February 2022
Mending the Model for End‐Stage Liver Disease: An in‐depth review of the past, present, and future portopulmonary hypertension Model for End‐Stage Liver Disease exception
Hilary M. DuBrock, Kathryn T. Valle, Michael J. Krowka – 1 February 2022 – Patients with portopulmonary hypertension (POPH) have an increased cardiovascular and overall mortality risk when undergoing liver transplantation (LT). However, such risk is not captured in their Model for End‐Stage Liver Disease (MELD) laboratory score. POPH MELD exception criteria were established in 2006 with the aim of prioritizing these patients for LT prior to pulmonary hypertension (PH) progression and eventual right heart failure.
Tumor‐derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression
Chubin Luo, Haoyang Xin, Zhengjun Zhou, Zhiqiang Hu, Rongqi Sun, Na Yao, Qiman Sun, Uyunbilig Borjigin, Xia Wu, Jia Fan, Xiaowu Huang, Shaolai Zhou, Jian Zhou – 1 February 2022
Reply
Victor H. F. Lee, Tiffany C. L. Wong – 1 February 2022
AASLD Practice Guidance: Palliative care and symptom‐based management in decompensated cirrhosis
Shari S. Rogal, Lissi Hansen, Arpan Patel, Nneka N. Ufere, Manisha Verma, Christopher D. Woodrell, Fasiha Kanwal – 31 January 2022